Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac Muscle
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Systemic delivery of recombinant adeno-associated virus (rAAV) 6 vectors mediates efficient transduction of the entire striated musculature, making this an attractive strategy for muscle gene therapy. However, owing to widespread transduction of non-muscle tissues, optimization of this method would benefit from the use of muscle-specific promoters. Most such promoters either lack high-level expression in certain muscle types or are too large for inclusion in rAAV vectors encoding microdystrophin. Here, we describe novel regulatory cassettes based on enhancer/promoter regions of murine muscle creatine kinase (CK) and alpha-myosin heavy-chain genes. The strongest cassette, MHCK7 (770 bp), directs high-level expression comparable to cytomegalovirus and Rous sarcoma virus promoters in fast and slow skeletal and cardiac muscle, and low expression in the liver, lung, and spleen following systemic rAAV6 delivery in mice. Compared with CK6, our previous best cassette, MHCK7 activity is approximately 400-, approximately 50-, and approximately 10-fold higher in cardiac, diaphragm, and soleus muscles, respectively. MHCK7 also directs strong microdystrophin expression in mdx muscles. While further study of immune responses to MHCK7-regulated microdystrophin expression is needed, this cassette is not active in dendritic cell lines. MHCK7 is thus a highly improved regulatory cassette for experimental studies of rAAV-mediated transduction of striated muscle.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [135]
Citations
Cites
Three myosin heavy chain isoforms in type 2 skeletal muscle fibres
Schiaffino, S., Gorza, L., Sartore, S., Saggin, L., Ausoni, S., Vianello, M., Gundersen, K., & LØmo, T. (1989) · Journal of Muscle Research and Cell Motility · doi:10.1007/bf01739810 · Cited by 954
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Self-citationKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Bottinelli, R., Schiaffino, S., & Reggiani, C. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018617 · Cited by 486
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Cited by
Items 201–232 of 232
Description of muscle disease – general aspects
Karpati, G. (2010) · Cited by 1
Systemic Gene Delivery for Muscle Gene Therapy
Garikipati, D. K., & Chamberlain, J. S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_10 · Cited by 2
Self-citationA gene therapy approach for the treatment of limb-girdle muscular dystrophy 2C/R5
Hermann, H. J., Wuebbles, R. D., & Burkin, D. J. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.004 · Cited by 1
Dietz, J., Jacobsen, F., Zhuge, H., Daya, N., Bigot, A., Zhang, W., Ehrhardt, A., Vorgerd, M., & Ehrke‐Schulz, E. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221574 · Cited by 1
“In the present study, we therefore focused on the comparison of the DES, MHCK7, miR206 and CAPN3 promotor as potential regulatory elements for efficient muscle gene therapy [5, 14, 17].”
BackgroundKornegay, J. N., Stedman, H. H., Lawlor, M. W., Byrne, B. J., & Childers, M. K. (2024) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.28 · Cited by 3
Promoter analysis of bovine cardiomyopathy-associated protein 1 gene
Sui, G. N., Liu, Z. W., Wang, T., Li, X., Ding, X. B., Liu, X. F., & Guo, H. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15027675 · Cited by 1
Construction of a Porcine Skeletal Muscle-Specific Promoter by Inducing the Seed Region of miR-208a
Zuo, X., Zhao, P., & Ren, Z. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00428-2 · Cited by 1
“[23] used the enhancer of MCK and α-myosin heavy chain (α-MHC) to increase the activity of the MCK promoter in the myocardium.”
MethodDevelopment of targeted gene delivery vectors to assess cardiac overexpresion of ACE2 in vivo
Shirley, R. (2008) · Enlighten: Theses (The University of Glasgow) · Cited by 3
The principles of molecular therapies for muscle diseases
Karpati, G., & Gilbert, R. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511674747.013 · Cited by 1
Gene Therapy and Muscles: The Use of Adeno-associated Virus—Where are We Today?
Wang, B. (2010) · Operative Techniques in Orthopaedics · doi:10.1053/j.oto.2009.10.011
Müller, O. J., & Katus, H. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-78709-9_9
Gene Therapy for the Respiratory Muscles
Danialou, G., & Petrof, B. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_3
Modulating Immune Responses in Muscle Gene Therapy
Arruda, V. R. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_11
“Hauschka and colleagues (Salva et al. 2007) developed a series of muscle-specific promoters by modification and optimization of a muscle creatine kinase (MCK)-based construct to fulfill the desirable tissue-specificity and high efficacy.”
BackgroundRapti, K., Chaanine, A. H., & Hajjar, R. J. (2011)
Sun, F., Zhang, J., Ma, C., Zhang, Y., Li, Y., Zhang, L., Deng, Y., & Ma, H. (2016)
The effect of emerging therapies on cardiopulmonary disease in Duchenne muscular dystrophyPreprint
Mckim, D. A., Cripe, T. P., & Cripe, L. H. (2020) · doi:10.22541/au.159654450.08846231
Strash, N., DeLuca, S., Carattini, G. L. J., Chen, Y., Scherba, J. C., Jain, M., Naseri, R., Wu, T., & Bursac, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.28.482357
Darbey, A. L., Jin, W., Greensmith, L., Sleigh, J. N., Counsell, J. R., & Fratta, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.02.605568
“Given the risks of toxicity associated with AAV transduction in the liver, we sought to further increase muscle-specificity of transgene expression by incorporating a muscle-specific promoter (MHCK7 11 ) into our AAV plasmid.”
BackgroundBecker, R., Choudhury, P., Oti, M., Fouani, Y., Strobel, B., Ketterer, S., Rumpel, S., Park, J., Kreuz, S., Maier, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.04.657008
“…in Roctavian (Bunting et al. 2018; McIntosh et al. 2013), Hemgenix (Nathwani et al. 2006) and Beqvez (George et al. 2017) for haemophilia therapy or the striated muscle-specific MHCK7 element in Elevidys for therapy of Duchenne’s muscular dystrophy (Mendell et al. 2020; Salva et al. 2007).”
Iammarino, M., Alonso‐Pérez, J., Stojkovic, T., Pegoraro, E., Lowes, L. P., Díaz‐Manera, J., Alonso‐Pérez, J., Borland, H., Bruno, C., Cárdenas, L., et al. (2025) · Neuromuscular Disorders · doi:10.1016/j.nmd.2025.106212
Muscle MRI in Duchenne muscular dystrophy patients after fordadistrogene movaparvovec
Sherlock, S. P., Shi, H., Li, H., Butterfield, R. J., Shieh, P. B., Smith, E. C., McDonnell, T. G., Ryan, K. A., Shen, Q., & Binks, M. H. (2026) · Future Neurology · doi:10.1080/14796708.2025.2607962
Thomsen, G. M., Kaspar, A. A., Ferraiuolo, L., Chu, B. T. T., Garcia, V. J., Weiss, R., Slaiwa, T. I., Casanova-Vallve, N., Cano, R., Hurley, E., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201707
“It includes the muscle-derived MHCK7 promoter that contains elements that drive expression of the myosin heavy chain kinase in muscle 30 ; an SV40 intron that has been used in gene therapy vectors to enhance translation of expressed RNA; the micro-dystrophin gene; and an SV40 poly(A) signal, which…”
Wu, T., Li, Y., Perelli, R. M., Siu, Y. Y., Tornatore, A., Moran, J. N., Jiang, X., DeLuca, S., Bers, D. M., Henriquez, C. S., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady4551
“S1A) ( 23 , 24 ).”
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Ye, J., Luo, C., Yang, Z., Fan, Y., Gu, L., Xu, G., You, X., Feng, Y., Wang, H., Jia, R., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168339
AAV Vector Toolkit for the Delivery and Expression of the Artificial microRNA in the Murine Heart
Galkin, I. I., Skopenkova, V. V., Shubina, M. Y., Polikarpova, A. V., Vassilieva, S. G., Savchenko, I. M., Лебедева, О. С., Goliusova, D. V., Sharikova, M. Y., Gureev, V. V., et al. (2026) · BioTech · doi:10.3390/biotech15030055
“The second group included pan-muscle-specific promoters murine MHCK7 [59], synthetic chicken SPc5-12 [60]), murine CK8e [61], murine desmin (mDes) [62], and human desmin (hDes) [62].”
Genome Editing for Glycogen Storage Diseases
von Beck, T. A., Wang, R., & Koeberl, D. D. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70249
“Additionally, transgene expression can provoke immune responses, especially when viral enhancers contained in the vectors drive expression in immune cells [4, 5].”
Yang, S., Kong, J. S., Shin, H. Y., Cho, S. C., Intisar, A., Kim, M. Y., CHOI, Y., Lee, Y., Cho, D., & Kim, M. S. (2026) · Small Science · doi:10.1002/smsc.70386
Li, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
Tordo, J. (2013) · UCL Discovery (University College London)
Novel approaches to thalassaemia gene therapy
Ferreira, S. (2013) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Metadata
- Authors
- Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., Chamberlain, J. S., & Hauschka, S. D.
- Affiliations
- University of Washington (US)
- Corresponding author
- Hauschka, Stephen D
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 15
- Issue
- 2
- Pages
- 320-329
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2065979540
- Cited by
- 232
- References
- 46
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 22 · 2023: 22 · 2022: 11 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 11
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3536 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R24HL064387)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR018860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007183, U54HD047175)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- muscle-specific promoter, muscle creatine kinase, alpha-myosin heavy chain, microdystrophin, mdx mice, skeletal muscle, myocardium, tissue-specific gene expression
- MeSH terms
- Dependovirus, Animals, Cell Line, Cells, Cultured, Cloning, Molecular, Creatine Kinase, Fluorescent Antibody Technique, Gene Expression Regulation, Genetic Vectors, Humans, Male, Mice, Inbred C57BL, Myocardium, Promoter Regions, Genetic, Transfection, Muscle, Skeletal, Ventricular Myosins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.